United States Drug Patent 8,603,506: Scope, Claims, Expiration, Orange Book Status, and Oracea Patent Landscape

U.S. Patent No. 8,603,506 protected low-dose oral doxycycline treatment for papules and pustules associated with rosacea. Its core limitation was a 40 mg-per-day, subantimicrobial doxycycline regimen that treats rosacea without reducing skin microflora over six months and without concomitant bisphosphonate administration. The patent covered methods of use, not the doxycycline molecule itself or a broad composition of matter.

The patent is part of the Oracea patent family associated with Galderma and its predecessors. Based on the patent family’s earliest priority date and the standard 20-year patent term, the patent’s ordinary expiration date was November 3, 2023, subject to any applicable patent-term adjustment or disclaimer. The patent is therefore no longer a blocking patent for new U.S. generic entry after that date. [1, 2]

What does U.S. Patent 8,603,506 cover?

U.S. Patent 8,603,506 covers methods for treating papules and pustules of rosacea by orally administering doxycycline at a dose below conventional antimicrobial levels.

The independent claims divide into three overlapping protection groups:

Claim group	Dose limitation	Additional requirements
Claim 1	10% to 80% of 50 mg per day, equivalent to 5 mg to 40 mg per day	Effective rosacea treatment; no reduction of skin microflora during six months; no bisphosphonate
Claim 8	40% to 80% of 50 mg per day, equivalent to 20 mg to 40 mg per day	Same microbiological and bisphosphonate limitations
Claim 15	40 mg per day	Same microbiological and bisphosphonate limitations

The broadest practical commercial coverage is claim 15 because it directly targets a 40 mg daily regimen. Claim 8 captures daily doses from 20 mg through 40 mg. Claim 1 reaches lower doses, but the claim remains limited by the requirement that the dose effectively treat rosacea and produce no reduction in skin microflora over six months.

The claims do not cover every use of doxycycline in rosacea. They require a specific clinical-use profile:

Oral administration.
Treatment of papules and pustules of rosacea.
A dose within the stated range.
No reduction of skin microflora during six months.
No administration of a bisphosphonate compound.

The patent does not claim doxycycline generally, doxycycline monohydrate as a chemical substance, or all controlled-release doxycycline products.

How do the dependent claims narrow the patent scope?

Claims 2 through 7 and claims 9 through 14 narrow the independent claims by specifying the doxycycline form, administration schedule, release profile, or serum concentration.

Dependent claims	Limitation
2, 9, 16	Doxycycline monohydrate
3, 10	40 mg
4, 11, 17	Sustained release
5, 12, 18	Once-daily administration
6, 13, 19	20 mg twice daily
7, 14, 20	Serum concentration of approximately 0.1 to 0.8 micrograms per milliliter

Claims 4, 5, 11, 12, 17, and 18 are especially relevant to Oracea because the product is a delayed-release 40 mg doxycycline monohydrate capsule administered once daily. Claims 3 and 10 also track the 40 mg dose.

The claims include both once-daily sustained release and 20 mg twice-daily dosing. This creates potential overlap between a branded delayed-release product and a generic immediate-release or divided-dose product if the generic product is marketed for the claimed rosacea indication.

What is the technical significance of the no-microflora limitation?

The no-microflora limitation distinguishes the claimed regimen from conventional antimicrobial doxycycline treatment.

Doxycycline is commonly administered at higher doses for bacterial infections. The patent’s commercial concept was to use a dose high enough to reduce inflammatory rosacea lesions but low enough to avoid meaningful antimicrobial activity. The claimed result was no reduction of skin microflora during six months of treatment.

That limitation creates both commercial value and enforcement complexity. It helps distinguish the claimed use from traditional antibiotic therapy, but it also raises proof questions:

Whether “no reduction” means no statistically significant reduction, no clinically meaningful reduction, or no measurable reduction.
Which skin microflora organisms must be evaluated.
Whether the result must be demonstrated in every patient or only shown by clinical data.
Whether a generic manufacturer’s product necessarily produces the same microbiological outcome.
Whether the limitation is treated as a method step, a required result, or both.

In patent litigation, a branded plaintiff would normally need to show that the accused product is indicated, labeled, or used in a manner that satisfies the dosage, rosacea, and microbiological limitations. A generic label that omits the patented indication can reduce inducement exposure, but it does not eliminate all possible infringement theories if substantial off-label use is alleged.

What formulations are protected by U.S. Patent 8,603,506?

The patent protects particular uses of doxycycline formulations rather than the formulation technology in the abstract.

The most relevant covered product profile is:

Doxycycline monohydrate.
40 mg per day.
Oral administration.
Sustained-release or delayed-release delivery.
Once-daily dosing.
Treatment of inflammatory papules and pustules of rosacea.

The patent also covers a 20 mg twice-daily regimen through claims 6, 13, and 19. A product administered as two 20 mg doses per day could fall within the claims if the remaining requirements are satisfied, including the six-month skin-microflora limitation.

The patent does not expressly require the specific pellet technology, capsule architecture, excipient system, or dissolution profile used by Oracea. Those attributes may be addressed in other formulation patents or regulatory records. A competing 40 mg doxycycline product could avoid infringement of a formulation-specific patent while still raising risk under these method claims.

What is the FDA regulatory status of Oracea?

The FDA approved Oracea delayed-release capsules under NDA 050805 in 2006 for the treatment of only inflammatory lesions, papules and pustules, of non-nodular moderate-to-severe rosacea in adults. Oracea contains 40 mg doxycycline, supplied as doxycycline monohydrate, and is administered once daily. [3]

The FDA labeling describes Oracea as a subantimicrobial-dose product. The label also states that Oracea is not indicated for the treatment or prevention of infections and should not be used to treat bacterial infections because the dosage does not provide adequate antimicrobial concentrations. [3]

This label closely corresponds to the claimed use in U.S. Patent 8,603,506. The regulatory indication therefore created a direct link between the product label and the patent’s method-of-use claims.

What was the Orange Book status of U.S. Patent 8,603,506?

U.S. Patent 8,603,506 was listed in the FDA Orange Book for Oracea and was one of several patents associated with the product’s low-dose doxycycline use and formulation protection. The Orange Book listing gave the patent practical relevance against ANDA applicants seeking approval for a therapeutically equivalent product. [2]

The relevant Orange Book framework was:

Issue	Effect
Patent listed for NDA product	ANDA applicant had to make a patent certification
Paragraph IV certification	Could trigger patent litigation
Timely infringement action	Could create a 30-month FDA approval stay
Patent expiration	Removed the patent-based bar to approval
Label carve-out	Could reduce risk for a generic omitting the rosacea indication

The patent’s expected expiration date was November 3, 2023. Any pediatric exclusivity, patent-term extension, patent-term adjustment, or terminal disclaimer would need to be confirmed in the current Orange Book and USPTO records. The patent family’s primary commercial blocking period has ended.

When did U.S. Patent 8,603,506 lose exclusivity?

The patent’s ordinary term ended on November 3, 2023, based on the earliest priority date associated with the Oracea rosacea patent family. The patent was issued on December 10, 2013, but the issuance date did not reset the patent term. [1]

The practical timeline was:

Date	Event
November 3, 2003	Earliest priority date associated with the relevant patent family
July 2006	FDA approval of Oracea
December 10, 2013	U.S. Patent 8,603,506 issued
2010s	ANDA and Paragraph IV disputes involving Oracea patents
November 3, 2023	Ordinary patent expiration date for the family
After November 3, 2023	No remaining ordinary exclusivity from this patent

The patent’s expiration did not eliminate other possible barriers, including later-issued formulation patents, regulatory exclusivity, trade secrets, manufacturing know-how, or separate patents covering delivery technology.

Which companies challenged the Oracea patent estate?

The Oracea franchise faced ANDA challenges from multiple generic companies. Public litigation and FDA records identify disputes involving generic applicants and manufacturers including Mylan, Amneal, Lupin, Taro, and other ANDA sponsors across the broader Oracea patent estate.

The litigation strategy generally focused on one or more of the following positions:

Invalidity based on obviousness.
Noninfringement based on a different formulation or dosing regimen.
Noninfringement based on a label that omitted the patented rosacea indication.
Expiration or unenforceability of earlier patents.
Lack of adequate written description or enablement for the microbiological limitation.
Distinction between delayed-release 40 mg doxycycline and other doxycycline products.

The relevant lawsuits were not necessarily directed only to Patent 8,603,506. Oracea litigation commonly involved multiple listed patents in a single action, including patents directed to methods, dosage regimens, and formulation characteristics.

What Paragraph IV risks applied to generic doxycycline 40 mg products?

A Paragraph IV applicant could challenge the patent by asserting that the patent was invalid, unenforceable, or not infringed. The principal risk analysis was claim-specific.

Infringement risk

A generic product faced the highest risk if its proposed label:

Named papules and pustules of rosacea as an indication.
Specified a 40 mg daily dose.
Used doxycycline monohydrate.
Used delayed-release or sustained-release administration.
Directed once-daily treatment for the branded indication.

A product with a 40 mg capsule but a label limited to an unpatented use could present a different risk profile. The product’s actual formulation and physician use would remain relevant to induced-infringement analysis.

Invalidity risk

The patent’s vulnerability centered on the combination of:

Low-dose doxycycline.
Clinical efficacy in rosacea.
Absence of skin-microflora reduction.
A six-month treatment period.
Exclusion of bisphosphonate administration.

An obviousness challenge could rely on prior art describing doxycycline treatment for rosacea, subantimicrobial dosing, anti-inflammatory tetracycline effects, and controlled-release formulations. The patentee’s response would likely emphasize the claimed clinical result and the distinction between antimicrobial and anti-inflammatory dosing.

Labeling risk

A generic applicant could seek a skinny label that omitted the rosacea indication. That approach may permit approval for a noninfringing use, but it can be less commercially attractive because the principal branded use is rosacea. A generic company would also need to evaluate whether the dosage form, promotional activity, prescribing patterns, and product design could support an inducement claim.

How strong was the patent estate for Oracea?

The estate was commercially strong during its active term because it aligned closely with the approved product:

The claimed 40 mg dose matched Oracea.
The claimed doxycycline monohydrate form matched the product.
The once-daily sustained-release claims matched the product presentation.
The rosacea indication matched the FDA label.
The subantimicrobial microbiological profile supported product differentiation.

Its principal weakness was that the estate relied heavily on method-of-use and result-oriented limitations. Those claims are narrower than composition-of-matter claims and are more sensitive to product labeling, actual use, clinical evidence, claim construction, and proof of induced infringement.

The estate also depended on a relatively old priority date. Continuation patents could extend prosecution and produce multiple enforceable claim sets, but they could not ordinarily extend the underlying 20-year patent term beyond the applicable statutory period.

How does Patent 8,603,506 compare with other Oracea patents?

Patent 8,603,506 should be analyzed as one layer of a multi-patent estate rather than as the entire Oracea franchise.

Patent category	Typical protection	Commercial relevance
Method-of-use patents	Low-dose doxycycline for rosacea	Directly protects the approved indication
Dose-regimen patents	40 mg once daily or divided dosing	Targets generic prescribing and label design
Formulation patents	Delayed-release or sustained-release delivery	Targets product architecture
Manufacturing patents	Pellet production, coating, or encapsulation	Can increase design-around cost
Later continuation patents	Refined claim scope	May preserve narrower claims after broad claims weaken

A generic manufacturer could avoid Patent 8,603,506 yet still face other patents if its product used the same delayed-release formulation or if the proposed label covered the same rosacea indication.

What is the competitive landscape after patent expiration?

After November 2023, the core patent-based barrier from U.S. Patent 8,603,506 no longer supports an ordinary infringement action based solely on its expired claims. Competition is therefore more likely to depend on:

FDA-approved ANDA status.
Therapeutic equivalence and substitution rules.
Manufacturing capacity.
Product quality and supply reliability.
Payer formulary placement.
Physician familiarity with 40 mg delayed-release doxycycline.
Remaining formulation or process patents.
Commercial settlements entered before expiration.

Doxycycline itself is an old active ingredient with broad generic availability. The commercial differentiation resides in the 40 mg delayed-release product, the approved rosacea indication, and the product’s controlled-exposure profile.

What revenue exposure did the patent protect?

Patent 8,603,506 protected revenue associated with Oracea’s principal indication rather than all doxycycline revenue. Its value was concentrated in the U.S. market for chronic treatment of inflammatory rosacea.

The economic exposure was significant because:

Oracea was a branded chronic-use product.
Rosacea treatment can require repeated or extended courses.
The 40 mg dose and delayed-release formulation differentiated the product from inexpensive generic doxycycline products.
A successful generic launch could create rapid price erosion through pharmacy substitution.
The branded product’s revenue depended on maintaining both indication and formulation differentiation.

Public company filings from Galderma’s predecessor entities and later corporate owners should be used for historical Oracea sales figures. Patent 8,603,506 itself does not establish product revenue or market share.

What geographic coverage did the patent provide?

The patent provided protection only in the United States. Foreign counterparts would require separate national rights and could have different claims, prosecution histories, expiration dates, and legal status.

The patent did not block:

Use of doxycycline outside the United States.
Manufacture outside the United States unless other statutory provisions applied.
Sale of noninfringing doxycycline products in the United States.
Generic products launched after expiration, subject to other live rights.

The geographic analysis must therefore separate U.S. patent expiry from Canadian, European, Japanese, and other national patent positions.

Key Takeaways

U.S. Patent 8,603,506 was a method-of-use patent for subantimicrobial oral doxycycline treatment of rosacea.
Its core commercial embodiment was doxycycline monohydrate 40 mg, administered once daily in a sustained- or delayed-release form.
The patent required no reduction of skin microflora during six months and no bisphosphonate administration.
It did not claim doxycycline as a molecule or broadly claim every doxycycline rosacea treatment.
The patent was listed in the Orange Book for Oracea.
Its ordinary expiration date was November 3, 2023.
Generic litigation focused on infringement, obviousness, label carve-outs, formulation differences, and the broader Oracea patent estate.
After expiration, remaining commercial barriers are more likely to arise from later patents, formulation know-how, FDA approval status, manufacturing, and market access.

FAQs

What dose of doxycycline is most directly covered by Patent 8,603,506?

The most commercially important dose is 40 mg per day. Claims 3, 10, and 15 directly address that dose, while other claims cover lower doses and 20 mg twice-daily administration.

Does Patent 8,603,506 cover immediate-release doxycycline?

Potentially, if the product and use satisfy all limitations of an asserted claim. The patent includes sustained-release and once-daily dependent claims, but the independent claims do not universally require a sustained-release formulation.

Can a generic sell doxycycline for acne after Patent 8,603,506 expires?

Yes, subject to FDA approval and any other live patents. The patent was directed to rosacea treatment, not acne treatment generally.

Does the patent cover topical doxycycline?

No. The claims require oral administration. A topical doxycycline product would not satisfy that express limitation.

Are biosimilars relevant to Oracea patent risk?

No. Oracea contains the small-molecule drug doxycycline, so the relevant competitors are generic ANDA products, not biosimilars under the FDA Biologics Price Competition and Innovation Act pathway.

References

United States Patent and Trademark Office. (2013). U.S. Patent No. 8,603,506, Methods of treating rosacea. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.). Oracea (doxycycline) delayed-release capsules, prescribing information. U.S. Department of Health and Human Services.
United States Court of Appeals for the Federal Circuit. (Various years). Galderma Laboratories, L.P. v. related ANDA defendants, patent litigation records concerning Oracea and doxycycline delayed-release products.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	330615	⤷ Start Trial
Australia	2002303250	⤷ Start Trial
Canada	2440472	⤷ Start Trial
Canada	2719162	⤷ Start Trial
Germany	60212613	⤷ Start Trial
Denmark	1383508	⤷ Start Trial
European Patent Office	1383508	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,603,506

Summary for Patent: 8,603,506